Ukko

Palo Alto, United States

Ukko is a biotechnology company focused on developing immunotherapies for the treatment of allergies and other immune-mediated diseases.

$45.0M raised

Jan 2026

Series C

Top Investors

Khosla VenturesPeakBridgeInnovation EndeavorsIsrael Biotech FundFall Line Capital

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Ukko raised?

Ukko has raised $45.0M in total funding. The most recent round was Series C. The last funding was announced in January 2026.

Who are Ukko's investors?

Ukko's investors include Khosla Ventures, PeakBridge, Innovation Endeavors, Israel Biotech Fund, Fall Line Capital.

Where is Ukko headquartered?

Ukko is headquartered in Palo Alto, United States.

What does Ukko do?

Ukko is a biotechnology company focused on developing immunotherapies for the treatment of allergies and other immune-mediated diseases.

What stage is Ukko at?

Ukko is at the Series C stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 8, 2026.

MLA

"Ukko — Funding & Investors." VCBacked, January 8, 2026, https://www.vcbacked.co/company/ukko. Accessed June 3, 2026.

APA

VCBacked. (2026). Ukko — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/ukko

Wikipedia (cite web)

{{cite web |title=Ukko — Funding & Investors |url=https://www.vcbacked.co/company/ukko |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 8, 2026.